A Phase 2 interventional study of Prasugrel and Clopidogrel in Acute Coronary Syndrome, sponsored by Eli Lilly and Company. Completed at 3 sites in India. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2012-11-20.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies testing clopidogrel in Acute Coronary Syndrome — 3 open to participants now, 3 under way, none of them phase 3. Clopidogrel · Acute Coronary Syndrome.
Among the 34 studies testing clopidogrel in Acute Coronary Syndrome, this one is the 13th largest by enrollment of the 33 interventional ones that give a count, is one of 4 that started in 2010, is one of 5 in phase 2, and was the 8th registered.
1,491 studies on the registry are indexed under Acute Coronary Syndrome; 273 are open to participants now.
Browse Acute Coronary Syndrome studies →3 of the 34 studies testing clopidogrel in Acute Coronary Syndrome are open now, in 3 countries. Recruiting first, the newest first:
China National Center for Cardiovascular Diseases · Sites in China
Ages 18–75
St. Antonius Hospital · Sites in Netherlands
Ages 18+ · Healthy volunteers
Samsung Medical Center · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Clopidogrel: first FDA approval 1997 (PLAVIX), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →
Of the 196 Acute Coronary Syndrome studies recruiting now, 145 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 9 · Phase 4 18
First in 2003; this study’s year is marked. 4 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 282 is above the median of 200 across 868 interventional studies indexed under Acute Coronary Syndrome.
Median enrollment 200 across the 33 interventional studies. Of the 25 that completed or were terminated, 6 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 34 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Eli Lilly and Company has 9 studies filed under Acute Coronary Syndrome — fewer than ten, so there is no comparison to draw.
1 of the studies testing clopidogrel in Acute Coronary Syndrome that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05638867China National Center for Cardiovascular DiseasesNOAC Therapy Guided by PARIS Risk Score and D-dimer in Patients With ACS After PCI | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies testing clopidogrel in Acute Coronary Syndrome, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with acute coronary syndrome (ACS). Platelet inhibition following a prasugrel LD in clopidogrel pretreated patients' will be determined in a time-dependent manner for two different prasugrel loading doses (30 mg and 60 mg). Understanding the effects of this combination on platelet inhibition will provide guidance to physicians on the use of prasugrel in patients who have already been pretreated with clopidogrel.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo loading dose administered once orally before percutaneous coronary intervention (PCI) and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
Drug: Prasugrel · Drug: Placebo
600-mg clopidogrel loading dose administered once orally before PCI and 60-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
Drug: Prasugrel · Drug: Clopidogrel
600-mg clopidogrel loading dose administered once orally before PCI and 30-mg prasugrel loading dose administered once orally during PCI, followed by 10-mg prasugrel maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
Drug: Prasugrel · Drug: Clopidogrel
Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
Also known as: LY640315
Loading dose administered once orally.
Loading dose administered once orally
Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD)
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
Time frame: 6 hours after prasugrel loading dose
Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation at Baseline, 2, 24 and 72 Hours After Prasugrel Loading Dose (LD)
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
Time frame: Baseline and 2 hours and 24 hours and 72 hours after prasugrel loading dose
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit
Time frame: Baseline, 72 hours
Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin
Time frame: Baseline, 72 hours
Percentage of Inhibition of Platelet Aggregation
Adenosine Diphosphate (ADP)-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. The internal BASE standard is an independent measurement and serves as an estimate of the participant's baseline platelet aggregation independent of P2Y12 receptor inhibition. Percent Inhibition of Platelet Aggregation=(1-\[PRU/BASE) x 100%, high numbers represent increased platelet inhibition. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
Time frame: Baseline and 2 and 6 and 24 and 72 hours after loading dose
Percentage of Poor Responders
Poor responders are those who had P2Y12 Reaction Units (PRU)≥ 240.
Time frame: Baseline and 2 and 6 and 24 and 72 hours after loading dose
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
TEAE is a worsening or new occurrence of adverse event (AE) during treatment compared to baseline. A summary of serious adverse events (SAE) and other nonserious AE are located in the Reported Adverse Events section.
Time frame: Baseline through 72 hours after prasugrel loading dose
P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.
Time frame: Baseline
P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM)
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.
Time frame: 6 hours after prasugrel loading dose
| Milestone | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Started | 110 | 83 | 89 |
| Received any treatment | 109 | 79 | 88 |
| Pharmacodynamic (pd) population | 52 | 47 | 50 |
| Completed | 85 | 62 | 62 |
| Not completed | 25 | 21 | 27 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 |
| Withdrew: Physician decision | 18 | 15 | 17 |
| Withdrew: Withdrawal by subject | 6 | 6 | 9 |
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
| PRU | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Adenosine Diphosphate (ADP)-Induced P2Y12 Receptor-Mediated Platelet Aggregation 6 Hours After Prasugrel Loading Dose (LD) | 57.86 ± 11.86 | 35.61 ± 12.36 | 53.92 ± 11.74 |
ADP-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
| PRU | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Baseline | 265.51 ± 13.01 | 248.58 ± 13.99 | 229.62 ± 13.38 |
| 2 Hours after Prasugrel LD | 122.55 ± 17.28 | 113.10 ± 18.07 | 117.10 ± 17.47 |
| 24 Hours after Prasugrel LD | 62.73 ± 10.43 | 34.05 ± 10.88 | 51.43 ± 10.72 |
| 72 Hours after Prasugrel LD | 56.95 ± 8.40 | 48.08 ± 9.09 | 60.29 ± 9.05 |
| proportion of 1.0 | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hematocrit | 0.0 ± 0.04 | 0.0 ± 0.03 | 0.0 ± 0.03 |
| gram per deciliter (g/dL) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Mean Change From Baseline to 72 Hours in Laboratory Measurements - Hemoglobin | -0.9 ± 1.41 | -0.6 ± 1.03 | -0.6 ± 1.04 |
Adenosine Diphosphate (ADP)-induced P2Y12 receptor mediated platelet aggregation serves as a biomarker of platelet function. It is measured in P2Y12 Reaction Units (PRU) with lower PRU reflecting stronger inhibition of P2Y12 and reduced platelet aggregation. The internal BASE standard is an independent measurement and serves as an estimate of the participant's baseline platelet aggregation independent of P2Y12 receptor inhibition. Percent Inhibition of Platelet Aggregation=(1-\[PRU/BASE) x 100%, high numbers represent increased platelet inhibition. Least Squares (LS) Mean values were controlled for treatment, visit, treatment and visit interaction, and country.
| percentage of inhibition | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Baseline | 9.71 ± 3.44 | 13.02 ± 3.70 | 14.94 ± 3.54 |
| 2 Hours after Prasugrel LD | 56.04 ± 5.88 | 58.75 ± 6.16 | 54.89 ± 5.95 |
| 6 Hours after Prasugrel LD | 79.87 ± 3.95 | 86.77 ± 4.13 | 78.55 ± 3.93 |
| 24 Hours after Prasugrel LD | 77.57 ± 3.56 | 87.64 ± 3.74 | 78.56 ± 3.68 |
| 72 Hours after Prasugrel LD | 78.48 ± 2.95 | 83.51 ± 3.28 | 78.17 ± 3.27 |
Poor responders are those who had P2Y12 Reaction Units (PRU)≥ 240.
| percentage of participants | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Baseline | 68.1 | 66.7 | 51.2 |
| 2 Hours after Prasugrel LD | 23.3 | 12.8 | 21.4 |
| 6 Hours after Prasugrel LD | 11.6 | 5.3 | 4.4 |
| 24 Hours after Prasugrel LD | 9.5 | 2.9 | 8.8 |
| 72 Hours after Prasugrel LD | 0 | 0 | 0 |
TEAE is a worsening or new occurrence of adverse event (AE) during treatment compared to baseline. A summary of serious adverse events (SAE) and other nonserious AE are located in the Reported Adverse Events section.
| participants | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Serious Adverse Events | 2 | 8 | 1 |
| Nonserious Adverse Events | 37 | 31 | 31 |
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.
| PRU | Clopidogrel at Baseline -CYP2C19 EM | Clopidogrel at Baseline - CYP2C19 RM |
|---|---|---|
| P2Y12 Reaction Units (PRU) of Clopidogrel Treated Participants at Baseline by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - CYP2C19 Extensive Metabolizers (EM) and Reduced Metabolizers (RM) | 243.549 ± 11.244 | 240.100 ± 17.955 |
CYP2C19 is a drug metabolizing enzyme. CYP2C19 Extensive metabolizers (EM) are individuals with two fully active / normal function CYP2C19 alleles (\*1/\*1, \*1/\*17). CYP2C19 Reduced metabolizers (RM) are individuals with at least one reduced-function CYP2C19 allele (\*2/\*2, \*1/\*2). Least Squares (LS) Mean values were controlled for CYP2C19 genetic group.
| PRU | Placebo and 60 mg Prasugrel-CYP2C19 EM | Placebo and 60 mg Prasugrel -CYP2C19 RM | 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 EM | 600 mg Clopidogrel and 60 mg Prasugrel - CYP2C19 RM | 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 EM | 600 mg Clopidogrel and 30 mg Prasugrel - CYP2C19 RM |
|---|---|---|---|---|---|---|
| P2Y12 Reaction Units (PRU) at 6 Hours Post-Prasugrel Loading Dose (LD) by Cytochrome P450 2C19 (CYP2C19)-Predicted Functional Groups - Extensive Metabolizers (EM) and Reduced Metabolizers (RM) | 39.036 ± 11.397 | 47.750 ± 30.153 | 20.190 ± 13.160 | 23.625 ± 21.321 | 36.478 ± 12.575 | 24.778 ± 20.102 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo and 60-mg Prasugrel | — | 2/109 (1.8%) | 37/109 (33.9%) |
| 600-mg Clopidogrel and 60-mg Prasugrel | — | 8/79 (10.1%) | 31/79 (39.2%) |
| 600-mg Clopidogrel and 30-mg Prasugrel | — | 1/88 (1.1%) | 31/88 (35.2%) |
| Event | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| Coronary artery occlusionCardiac disorders | 0/109 | 2/79 | 0/88 |
| Acute myocardial infarctionCardiac disorders | 0/109 | 1/79 | 0/88 |
| Cardiac tamponadeCardiac disorders | 0/109 | 1/79 | 0/88 |
| Coronary artery diseaseCardiac disorders | 0/109 | 1/79 | 0/88 |
| Pericardial effusionCardiac disorders | 0/109 | 1/79 | 0/88 |
| Ventricular fibrillationCardiac disorders | 0/109 | 1/79 | 0/88 |
| HaematemesisGastrointestinal disorders | 0/109 | 1/79 | 0/88 |
| Femoral artery dissectionVascular disorders | 0/109 | 1/79 | 0/88 |
| HypotensionVascular disorders | 0/109 | 1/79 | 0/88 |
| Myocardial infarctionCardiac disorders | 0/109 | 0/79 | 1/88 |
| Event | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel |
|---|---|---|---|
| High density lipoprotein decreasedInvestigations | 8/109 | 7/79 | 7/88 |
| HypokalaemiaMetabolism and nutrition disorders | 6/109 | 3/79 | 6/88 |
| DyslipidaemiaMetabolism and nutrition disorders | 5/109 | 4/79 | 2/88 |
| HeadacheNervous system disorders | 3/109 | 4/79 | 4/88 |
| InsomniaPsychiatric disorders | 0/109 | 3/79 | 0/88 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 4/109 | 1/79 | 0/88 |
| HypomagnesaemiaMetabolism and nutrition disorders | 3/109 | 1/79 | 3/88 |
| ConstipationGastrointestinal disorders | 3/109 | 0/79 | 1/88 |
| NauseaGastrointestinal disorders | 3/109 | 2/79 | 2/88 |
| Angina pectorisCardiac disorders | 0/109 | 2/79 | 0/88 |
| Age Continuous(years) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| Mean | 58.1 ± 9.47 | 57.5 ± 9.12 | 58.7 ± 8.07 | 58.1 ± 8.86 |
| Sex: Female, Male(Participants) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| Female | 13 | 8 | 9 | 30 |
| Male | 39 | 39 | 41 | 119 |
| Ethnicity (NIH/OMB)(Participants) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| Hispanic or Latino | 13 | 14 | 13 | 40 |
| Not Hispanic or Latino | 30 | 28 | 30 | 88 |
| Unknown or Not Reported | 9 | 5 | 7 | 21 |
| Race (NIH/OMB)(Participants) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 13 | 12 | 9 | 34 |
| Native Hawaiian or Other Pacific Islander | 1 | 2 | 0 | 3 |
| Black or African American | 1 | 2 | 3 | 6 |
| White | 37 | 31 | 38 | 106 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| India | 10 | 11 | 9 | 30 |
| Argentina | 2 | 4 | 4 | 10 |
| Brazil | 6 | 5 | 6 | 17 |
| Australia | 1 | 3 | 2 | 6 |
| Canada | 11 | 8 | 10 | 29 |
| Mexico | 8 | 6 | 5 | 19 |
| Turkey | 7 | 2 | 7 | 16 |
| United States | 7 | 8 | 7 | 22 |
| Qualifying Acute Coronary Syndrome (ACS) Event(participants) | Placebo and 60-mg Prasugrel | 600-mg Clopidogrel and 60-mg Prasugrel | 600-mg Clopidogrel and 30-mg Prasugrel | Total |
|---|---|---|---|---|
| Unstable Angina | 21 | 16 | 22 | 59 |
| Non-ST-elevation Myocardial Infarction | 20 | 18 | 21 | 59 |
| ST-elevation Myocardial Infarction | 11 | 13 | 7 | 31 |
The record gives a start of May 2010, a primary completion of Nov 2011 and a completion of Nov 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clopidogrel